JP2015532096A5 - - Google Patents

Download PDF

Info

Publication number
JP2015532096A5
JP2015532096A5 JP2015534771A JP2015534771A JP2015532096A5 JP 2015532096 A5 JP2015532096 A5 JP 2015532096A5 JP 2015534771 A JP2015534771 A JP 2015534771A JP 2015534771 A JP2015534771 A JP 2015534771A JP 2015532096 A5 JP2015532096 A5 JP 2015532096A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
aoi
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015534771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015532096A (ja
JP6351598B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062410 external-priority patent/WO2014055370A1/en
Publication of JP2015532096A publication Critical patent/JP2015532096A/ja
Publication of JP2015532096A5 publication Critical patent/JP2015532096A5/ja
Application granted granted Critical
Publication of JP6351598B2 publication Critical patent/JP6351598B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015534771A 2012-10-01 2013-09-27 糖タンパク質を産生するための組成物および方法 Active JP6351598B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261708554P 2012-10-01 2012-10-01
US61/708,554 2012-10-01
PCT/US2013/062410 WO2014055370A1 (en) 2012-10-01 2013-09-27 Compostions and methods for producing glycoproteins

Publications (3)

Publication Number Publication Date
JP2015532096A JP2015532096A (ja) 2015-11-09
JP2015532096A5 true JP2015532096A5 (enExample) 2016-11-17
JP6351598B2 JP6351598B2 (ja) 2018-07-04

Family

ID=49354940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534771A Active JP6351598B2 (ja) 2012-10-01 2013-09-27 糖タンパク質を産生するための組成物および方法

Country Status (28)

Country Link
US (2) US20150259425A1 (enExample)
EP (1) EP2904092B1 (enExample)
JP (1) JP6351598B2 (enExample)
KR (1) KR102182885B1 (enExample)
CN (1) CN104797707A (enExample)
AU (1) AU2013327681B2 (enExample)
BR (1) BR112015007319B1 (enExample)
CA (1) CA2886753C (enExample)
CY (1) CY1119602T1 (enExample)
DK (1) DK2904092T3 (enExample)
EA (1) EA201590550A1 (enExample)
ES (1) ES2646594T3 (enExample)
HK (1) HK1207394A1 (enExample)
HR (1) HRP20171753T1 (enExample)
HU (1) HUE034896T2 (enExample)
IL (1) IL237916A0 (enExample)
IN (1) IN2015DN02630A (enExample)
LT (1) LT2904092T (enExample)
ME (1) ME02882B (enExample)
MX (1) MX366106B (enExample)
NO (1) NO2760138T3 (enExample)
PL (1) PL2904092T3 (enExample)
PT (1) PT2904092T (enExample)
RS (1) RS56641B1 (enExample)
SG (2) SG11201502339YA (enExample)
SI (1) SI2904092T1 (enExample)
SM (1) SMT201700588T1 (enExample)
WO (1) WO2014055370A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6526025B2 (ja) 2013-10-16 2019-06-05 オンコバイオロジクス,インコーポレイティド 抗体安定性を増強する緩衝液製剤
EP3212668B1 (en) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2017120359A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
MX2018008447A (es) * 2016-01-06 2019-05-30 Oncobiologics Inc Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
MX2018009341A (es) 2016-02-03 2019-05-15 Oncobiologics Inc Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
EP3420072B1 (en) 2016-02-22 2025-06-18 Agency for Science, Technology and Research Cell culture medium
CA3043640A1 (en) * 2016-11-11 2018-05-17 Whitehead Institute For Biomedical Research Human plasma-like medium
IL276910B2 (en) 2018-03-26 2025-11-01 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
EP3806871A4 (en) 2018-06-12 2022-02-23 The Regents of the University of California SINGLE-CHAIN BISPECIFIC CHEMICAL ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER
WO2020215021A1 (en) * 2019-04-18 2020-10-22 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
CN113337562B (zh) * 2021-05-24 2022-06-03 宁波人健药业集团股份有限公司 使用CHO细胞高效发酵生产rhCG的方法
CN113480632B (zh) * 2021-07-30 2023-02-03 宁波人健药业集团股份有限公司 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DE60230858D1 (de) * 2001-02-15 2009-03-05 Centocor Inc Chemisch definiertes medium für kultivierte säugerzellen
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
AU2005226736B2 (en) 2004-03-24 2009-11-26 Abbvie Biotherapeutics Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
WO2009020933A2 (en) 2007-08-03 2009-02-12 Facet Biotech Corporation Therapeutic use of anti-tweak receptor antibodies

Similar Documents

Publication Publication Date Title
JP2015532096A5 (enExample)
HRP20171753T1 (hr) Pripravci i postupci za proizvodnju glikoproteina
SG11201901495YA (en) Method for producing antibody fusion protein
EP2522724A4 (en) POLYPEPTIDE MODIFYING METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
MY197200A (en) Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
JP2011525355A5 (enExample)
EA201690600A1 (ru) Метаболически оптимизированная клеточная культура
JP2012143232A5 (enExample)
IL310186B1 (en) Plasma kallikrein binding proteins
HRP20191409T1 (hr) Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
MY169935A (en) "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
MX2015000683A (es) Metodo para producir moleculas monomericas y multimericas y uso de las mismas.
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
NZ596595A (en) Method for orthopoxvirus production and purification
WO2010013947A3 (ko) 자연살해세포의 증식방법
NZ597742A (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
JP2017508523A5 (enExample)
SG10201803982TA (en) Antibodies and processes for preparing the same
PL439807A1 (pl) Sposoby oczyszczania przeciwciał i ich kompozycje
JP2016513478A5 (enExample)
WO2015010118A3 (en) Transthyretin amyloid-selective and polyreactive catabodies
JP2017520531A5 (enExample)
MY184072A (en) Increasing virus like particle yield in plants
HRP20231139T1 (hr) Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.